UPPP (Uvulopalatopharyngoplasty): Efficacy and Risks
Uvulopalatopharyngoplasty, commonly abbreviated UPPP, is the most widely performed surgical procedure for snoring and obstructive sleep apnea. The surgery removes or repositions excess tissue from the soft palate, uvula, and tonsillar pillars to widen the upper airway. It is performed under general anesthesia, typically requires one to two nights of hospitalization, and involves a recovery period of two to four weeks during which swallowing is painful and diet is restricted to soft foods.
The efficacy data for UPPP is mixed and has been a source of ongoing debate in sleep medicine. Short-term success rates — defined as a 50 percent or greater reduction in AHI — range from 40 to 60 percent in published studies, but long-term data is less favorable. A systematic review in Laryngoscope found that AHI reductions achieved at 6 months often deteriorate by 5 years as residual pharyngeal tissues continue to relax with aging and weight changes. Risks include post-operative bleeding, infection, velopharyngeal insufficiency (nasal regurgitation), and permanent changes to voice quality. The American Academy of Dental Sleep Medicine recommends that oral appliance therapy be trialed before surgical options are considered for most patients with simple snoring or mild-moderate OSA.
Somnoplasty and Radiofrequency Ablation
Radiofrequency ablation (RFA), marketed under the brand name Somnoplasty, is a minimally invasive office procedure that uses low-level radiofrequency energy to create controlled lesions in the soft palate, turbinates, or tongue base. As these lesions heal over two to eight weeks, the targeted tissue stiffens and shrinks, reducing the floppiness that causes vibration-related snoring. The procedure is performed under local anesthesia and takes approximately 30 minutes, with significantly less post-operative pain and shorter recovery than UPPP.
Clinical results are modest. Studies report snoring reduction in 70 to 80 percent of patients immediately after treatment, but recurrence rates are substantial — many patients require repeat treatments within one to three years as tissue laxity returns. RFA is most effective for palatal snoring specifically and is less effective when tongue base or lateral pharyngeal wall collapse is the dominant mechanism. Cost ranges from $1,500 to $3,000 per session out-of-pocket, as most insurance plans do not cover snoring procedures. For patients with simple palatal snoring who have failed conservative therapy, RFA represents a reasonable intermediate step before more invasive surgery.
Hypoglossal Nerve Stimulation (Inspire Therapy)
Hypoglossal nerve stimulation, sold under the brand name Inspire, is a surgically implanted neurostimulation device approved by the FDA for moderate-to-severe OSA in patients who cannot tolerate CPAP. The system consists of a sensing lead in the chest wall, a neurostimulator implanted below the collarbone, and a stimulation lead attached to the hypoglossal nerve. During sleep, the device senses respiratory effort and delivers a mild electrical impulse that activates the genioglossus muscle, protracting the tongue and preventing airway collapse.
Clinical evidence for Inspire is substantially stronger than for most other surgical options. The pivotal STAR trial published in the New England Journal of Medicine demonstrated a 68 percent median reduction in AHI at 12 months, with 86 percent of bed partners reporting no or soft snoring. Long-term follow-up studies show durable benefit at 5 years. However, Inspire is indicated for OSA, not simple snoring, and eligibility requires a drug-induced sleep endoscopy to confirm the absence of complete concentric collapse of the soft palate (a pattern that predicts poor Inspire response). The procedure costs approximately $30,000 to $40,000 and requires ongoing battery replacement every 10 to 11 years. It is a highly effective option for the right candidate but represents significant surgical intervention compared to conservative alternatives like the Snorple mouthpiece.
Laser-Assisted Uvulopalatoplasty (LAUP)
Laser-assisted uvulopalatoplasty uses a CO2 laser to vaporize portions of the uvula and make serial notches in the soft palate, creating scar tissue that stiffens and shortens the palate over multiple treatment sessions. Each session takes approximately 20 to 30 minutes under local anesthesia, and most protocols involve three to five sessions spaced four to six weeks apart. Early enthusiasm for LAUP in the 1990s was substantial, as it promised a less invasive alternative to UPPP.
However, long-term data has been disappointing. A 2003 position statement by the American Academy of Sleep Medicine concluded that LAUP is not recommended for OSA treatment due to insufficient and conflicting evidence, and its use has declined substantially since. For simple snoring without OSA, short-term results are comparable to UPPP, but long-term durability is poor. There are also concerns about post-operative scar tissue formation that can, paradoxically, worsen airway dynamics in some patients. LAUP is now largely supplanted by radiofrequency ablation techniques in practices that still offer in-office soft palate procedures.
When Surgery Is Appropriate vs First-Line Device Therapy
The clinical decision between surgery and device therapy depends on several converging factors: OSA severity, anatomical findings, CPAP tolerance, and patient preference. For simple snoring without diagnosed OSA, the evidence strongly favors starting with conservative measures. An oral appliance like the Snorple mouthpiece costs roughly $60, carries no surgical risk, is reversible, and produces clinically significant snoring reduction in the majority of compliant users. Surgery carries real risks of complications, significant costs, and no guarantee of long-term success — factors that tip the risk-benefit calculus heavily toward device therapy for anyone who has not yet tried it.
Surgery becomes more appropriate when: (1) anatomical findings clearly identify a surgically correctable obstruction (e.g., markedly enlarged tonsils, severely elongated uvula, significant nasal septal deviation); (2) conservative therapy has been genuinely and consistently trialed for at least 90 days without adequate response; or (3) the patient has severe OSA with confirmed poor CPAP compliance and needs a more definitive intervention. The Harvard Health guidance on snoring treatment and the National Sleep Foundation both emphasize that surgery should follow, not precede, a thorough trial of non-surgical options. Reversible, evidence-based device therapy remains the appropriate first-line approach for the overwhelming majority of habitual snorers.
Take Action Tonight
If snoring affects you or someone you love, the solution does not have to be complicated or expensive. The Snorple mouthpiece uses dual MAD and TSD technology to keep your airway open naturally while you sleep.